Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection

Ichinohe, Takeshi; Watanabe, Izumi; Ito, Satoshi; Fujii, Hideki; Moriyama, Masami; Tamura, Shinichi; Takahashi, Hitomi; Sawa, Hirofumi; Chiba, Joe; Kurata, Takeshi; Sata, Tetsutaro; Hasegawa, Hideki

doi:10.1128/jvi.79.5.2910-2919.2005

Cited by 237 publications

(218 citation statements)

References 37 publications

Supporting

Mentioning

213

Contrasting

Order By: Relevance

“…It has been reported in different mouse studies that i.n. vaccination with adjuvanted WIV (Joo et al, 2010) or split viruses (Ichinohe et al, 2005;Ichinohe et al, 2006;Saluja et al, 2010) effective induction of serum IgG titers (Tseng et al, 2009). …”

Section: Resultsmentioning

confidence: 99%

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Geus

Haarlem

Poetri

et al. 2011

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

a b s t r a c tIn the poultry industry, infections with avian influenza virus (AIV) can result in significant economic losses. The risk and the size of an outbreak might be restricted by vaccination of poultry. A vaccine that would be used for rapid intervention during an outbreak should be safe to use, highly effective after a single administration and be suitable for mass application. A vaccine that could be applied by spray or aerosol would be suitable for mass application, but respiratory applied inactivated influenza is poorly immunogenic and needs to be adjuvanted. We chose aluminum OH, chitosan, cholera toxin B subunit (CT-B), and Stimune as adjuvant for an aerosolized vaccine with inactivated H9N2. Each adjuvant was tested in two doses. None of the adjuvanted vaccines induced AIV-specific antibodies after single vaccination, measured 1 and 3 weeks after vaccination by aerosol, in contrast to the intramuscularly applied vaccine. The aerosolized vaccine did enter the chickens' respiratory tract as CT-B-specific serum antibodies were detected after 1 week in chickens vaccinated with the CT-B-adjuvanted vaccine. Chickens showed no adverse effects after the aerosol vaccination based on weight gain and clinical signs. The failure to detect AIV-specific antibodies might be due to the concentration of the inactivated virus.

show abstract

Section: Resultsmentioning

confidence: 99%

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Geus

Haarlem

Poetri

et al. 2011

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

show abstract

“…Moreover, the activation of DCs without completely shutting down virus replication would further enhance DC-mediated transmission of HIV to T cells (55,70,72,74). Poly(I:C)-mediated activation through type I IFNs may be especially advantageous following mucosal (rather than systemic) application of poly(I:C) (35,73). Thus, poly(I:C) might have most potential as a topical strategy that could be applied immediately within 24 h after exposure to curb local spread.…”

Section: Discussionmentioning

confidence: 99%

Double-Stranded RNA Analog Poly(I:C) Inhibits Human Immunodeficiency Virus Amplification in Dendritic Cells via Type I Interferon-Mediated Activation of APOBEC3G

Trapp

Derby

Singer

et al. 2009

J Virol

View full text Add to dashboard Cite

show abstract

“…134 Poly(I:C) also induced functional CD8 + T-cell responses against OVA peptides in murine models; antigen-specific CD8 + responses were found not onto be strongly Type I IFN-dependent, 135 but also on the cytokine milieu provided by activated NK cells. 136 Although the strong adjuvantic properties of poly I:C have been validated in multiple immunization models including the induction of mucosal (IgA-mediated) immunity, [137][138][139][140][141][142] it remains to be seen whether the in vivo stability of poly(I:C) formulations would be sufficient to permit a detailed evaluation of its potential as an adjuvant in human trials.…”

Section: Intracellular Tlr3 Activation: Dsrna and Poly (I:c)mentioning

confidence: 99%

Potential adjuvantic properties of innate immune stimuli

et al. 2009

View full text Add to dashboard Cite

Just as the prescient comment by Gaston Ramon was relegated to the last footnote of his 1926 paper, 1 so has research on the mechanisms of action of adjuvants, until recently, languished as parenthetical annotations and addenda in the archives of immunology and vaccine development. Ramon defined immunological adjuvants as "substances used in combination with a specific antigen that produced a more robust immune response than the antigen alone." Interestingly enough, he was referring to his empirical findings that the addition of bread crumbs, tapioca, saponin and 'starch oil' to antigenic preparations greatly enhanced antibody responses to diphtheria or tetanus. 2 A year later, the adjuvanticity of aluminum salts (primarily phosphate and hydroxide) was discovered by Glenny and coworkers. 3 In the 83 years that have elapsed, the repertoire of investigational adjuvants has grown to encompass a very wide range of materials, 4 but aluminum salt-based mineral salts (generically, and incorrectly, termed "alum") have remained the only adjuvants currently approved by the FDA. Aluminum salts have enjoyed a good safety record, but they are weak adjuvants for antibody induction and induce a T helper-2 (T H 2)-skewed, rather than a T helper-1 (T H 1) response. 5,6 Furthermore, not only are aluminum salts ineffective at inducing cytotoxic T lymphocyte (CTL) or mucosal IgA antibody responses, but also have a propensity to induce IgE responses, which have been associated with allergic reactions in some subjects. 5,6 Very recent reports implicate the Nalp3 inflammasome, a component of the innate immune response, as the effector limb of alum-associated adjuvanticity. [7][8][9] In 1962, Dresser observed that injection of purified soluble proteins not only failed to stimulate an immune response, but tolerized animals unless a bacterial extract was admixed with the protein immunogen. 10 This led him to redefine adjuvanticity as "a property of a substance which can act as a physiological switch, directing at least some immunologically competent cells to respond by making antibody rather than by becoming immunologically paralyzed by the antigen," 11 confirming Johnson's earlier observations that lipopolysaccharide (LPS) from Gram-negative bacteria exerted potent adjuvant properties, 12 and perhaps paved the way for the subsequent discovery of the wide range of microorganism-derived adjuvants. 13 TLRs are pattern recognition receptors present on diverse cell types that recognize specific molecular patterns present in molecules that are broadly shared by pathogens but distinguishable from host molecules, collectively referred to as pathogen-associated molecular patterns (PAMPs). 14,15 There are 10 TLRs in the human genome;

show abstract

Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection

Cited by 237 publications

References 37 publications

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Double-Stranded RNA Analog Poly(I:C) Inhibits Human Immunodeficiency Virus Amplification in Dendritic Cells via Type I Interferon-Mediated Activation of APOBEC3G

Potential adjuvantic properties of innate immune stimuli

Contact Info

Product

Resources

About